 |
7 Diseases |  |
0 Trials |
|
0 Trials |  |
13 News |  |
- | LAPS-Insulin (HM12460A) / Hanmi
Journal: Preoperative oral carbohydrates in elderly patients undergoing free flap surgery for oral cancer: randomized controlled trial. (Pubmed Central) - Jul 8, 2022
Thirst (P = 0.001) and hunger (P = 0.003) differed significantly between the two groups prior to anaesthesia induction. The intake of oral carbohydrate 2 hours before surgery was both safe and effective for elderly patients with oral cancer undergoing free flap surgery and could relieve the physiological stress response.
- ||| LAPS-Insulin (HM12460A) / Hanmi
Trial termination: Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus (clinicaltrials.gov) - Apr 22, 2021
P1, N=21, Terminated, Sponsor: Hanmi Pharmaceutical Company Limited
The intake of oral carbohydrate 2 hours before surgery was both safe and effective for elderly patients with oral cancer undergoing free flap surgery and could relieve the physiological stress response. Suspended --> Terminated; Sopnsor decision
- LAPS-Insulin (HM12460A) / Hanmi
Trial completion date: Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus (clinicaltrials.gov) - Aug 12, 2020
P1, N=21, Suspended, Sponsor: Hanmi Pharmaceutical Company Limited
Suspended --> Terminated; Sopnsor decision Trial completion date: Sep 2019 --> Sep 2020
- | LAPS-Insulin (HM12460A) / Hanmi
Trial suspension: Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus (clinicaltrials.gov) - Sep 23, 2019
P1, N=21, Suspended, Sponsor: Hanmi Pharmaceutical Company Limited
Trial completion date: Sep 2019 --> Sep 2020 Terminated --> Suspended
- | LAPS-Insulin (HM12460A) / Hanmi
Enrollment change, Trial termination, Trial primary completion date: Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus (clinicaltrials.gov) - Sep 4, 2019
P1, N=21, Terminated, Sponsor: Hanmi Pharmaceutical Company Limited
Terminated --> Suspended N=48 --> 21 | Recruiting --> Terminated | Trial primary completion date: Jun 2019 --> Jan 2019; Sopnsor decision
- | LAPS-Insulin (HM12460A) / Hanmi
Trial completion, Trial completion date, Trial primary completion date: Molar Potency Study of HM12460A in Healthy Subjects (clinicaltrials.gov) - Feb 28, 2018
P1, N=38, Completed, Sponsor: Hanmi Pharmaceutical Company Limited
N=48 --> 21 | Recruiting --> Terminated | Trial primary completion date: Jun 2019 --> Jan 2019; Sopnsor decision Recruiting --> Completed | Trial primary completion date: Feb 2019 --> Feb 2018 | Trial completion date: Feb 2019 --> Feb 2018
- || LAPS-Insulin (HM12460A) / Hanmi
Enrollment change, Trial primary completion date: A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A (clinicaltrials.gov) - Nov 8, 2017
P1, N=86, Completed, Sponsor: Hanmi Pharmaceutical Company Limited
Recruiting --> Completed | Trial primary completion date: Feb 2019 --> Feb 2018 | Trial completion date: Feb 2019 --> Feb 2018 N=48 --> 86 | Trial primary completion date: Feb 2014 --> Jul 2014
- | LAPS-Insulin (HM12460A) / Hanmi
New P1 trial: Molar Potency Study of HM12460A in Healthy Subjects (clinicaltrials.gov) - Nov 6, 2017
P1, N=40, Recruiting, Sponsor: Hanmi Pharmaceutical Company Limited
- | LAPS-Insulin (HM12460A) / Hanmi
New P1 trial: Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus (clinicaltrials.gov) - Nov 6, 2017
P1, N=48, Recruiting, Sponsor: Hanmi Pharmaceutical Company Limited
- LAPS-Insulin (HM12460A) / Hanmi
Enrollment closed: A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A (clinicaltrials.gov) - Feb 5, 2014
P1, N=48, Active, not recruiting, Sponsor: Hanmi Pharmaceutical Company Limited
N=48 --> 86 | Trial primary completion date: Feb 2014 --> Jul 2014 Recruiting --> Active, not recruiting
- | LAPS-Insulin (HM12460A) / Hanmi
New P1 trial: A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A (clinicaltrials.gov) - Nov 8, 2012
P1, N=48, Active, not recruiting, Sponsor: Hanmi Pharmaceutical Company Limited